^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Adrenergic uptake inhibitor

    Related drugs:
    28d
    116130: Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinsons disease: a multi-center and multi-modal approach. (2024-516756-18-00)
    P2/3, N=20, Recruiting, Stichting Radboud universitair medisch centrum | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    AnTi-FREEZE: Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach (clinicaltrials.gov)
    P3, N=60, Recruiting, Radboud University Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    FORWARD: Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design (clinicaltrials.gov)
    P3, N=620, Recruiting, Axsome Therapeutics, Inc.
    New P3 trial
    2ms
    Populational pharmacokinetics of methylphenidate hydrochloride extended-release tablets in Chinese school-age children with attention-deficit/hyperactivity disorder (ChiCTR2500115500)
    P=N/A, N=60, Completed, Children's Hospital of Chongqing Medical University; Children's Hospital of Chongqing Medical University
    New trial
    3ms
    AnTi-FREEZE: Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach (clinicaltrials.gov)
    P3, N=60, Not yet recruiting, Radboud University Medical Center
    New P3 trial
    3ms
    Repositioning serotonergic antagonists as therapeutic agents in gastric cancer: induction of apoptosis, inhibition of cell migration, and cell cycle arrest in AGS cells. (PubMed, Cytotechnology)
    Imipramine induced G1/S phase arrest, whereas tropisetron, ketanserin, and cyproheptadine increased the sub-G1 cell population. Gene expression analysis revealed decreased Bcl-2 and PCNA levels and increased Bax expression.These findings suggest the potential of tropisetron, imipramine, ketanserin, and cyproheptadine as repurposed therapeutic agents for gastric cancer.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • PCNA (Proliferating cell nuclear antigen) • SLC6A4 (Solute Carrier Family 6 Member 4)
    |
    imipramine
    4ms
    The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans (clinicaltrials.gov)
    P2, N=48, Recruiting, VA Office of Research and Development | N=24 --> 48
    Enrollment change
    |
    imipramine
    4ms
    Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea (clinicaltrials.gov)
    P4, N=45, Completed, China Medical University Hospital | Recruiting --> Completed | N=132 --> 45
    Trial completion • Enrollment change
    4ms
    Characterization and Prognostic Impact of Fascin Expression in the Tumor Microenvironment of Triple-Negative Breast Cancer: Clues for a Tailored Therapy. (PubMed, Lab Invest)
    These findings highlight the dual role of fascin in tumor cells and the tumor microenvironment (TME), and reinforce its potential as a biomarker for personalized TNBC therapies. Ongoing clinical trials, including HITCLIF, are exploring the efficacy of imipramine in patients with fascin-overexpressing cancers, paving the way for targeted treatment strategies.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • FSCN1 (Fascin Actin-Bundling Protein 1)
    |
    HER-2 expression
    |
    imipramine
    4ms
    Progressive Relaxation and Psychoeducation in Patients With Hematological Malignancies (clinicaltrials.gov)
    P=N/A, N=75, Not yet recruiting, Necmettin Erbakan University
    New trial
    5ms
    Role of the Noradrenergic System in the Regulation of Learning Dynamics: Evaluation of the Effect of a Low-dose Selective Noradrenaline Reuptake Inhibitor (NOISYXETINE) (clinicaltrials.gov)
    P=N/A, N=160, Recruiting, Centre Hospitalier St Anne
    New trial
    6ms
    Sorafenib generates microvesicle particles in non-small cell lung cancer. (PubMed, Tumor Discov)
    Moreover, co-treatment with imipramine enhanced the cytotoxic effects of sorafenib, suggesting that targeting MVP-associated pathways may improve sorafenib response. Collectively, these findings offer mechanistic insight into how sorafenib modulates MVP release and supports the therapeutic potential of combining tyrosine kinase inhibitors with agents that disrupt MVP biogenesis in NSCLC.
    Journal
    |
    MVP (Major Vault Protein)
    |
    sorafenib • imipramine